BioNTech SE
BioNTech SE is named on 3 US grants and 4 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 3
- Published applications
- 4
- Inventors
- 15
- Granted in 2026 so far
- 0
- Most recent grant
- 13 Jun 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 1 |
| 2021 | 1 | 1 |
| 2022 | 1 | 0 |
| 2023 | 1 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 7 documents
Recent patents
- Compositions and methods for diagnosis and treatment of cancer13 Jun 2023US 11,673,939 B2
- Substituted imidazoquinolines8 Mar 2022US 11,267,813 B2
- Use of RNA for reprogramming somatic cells18 May 2021US 11,008,550 B2
- Methods and compositions for stimulating immune response30 Apr 2026US 2026/0115272 A1
- Compositions and Methods for Diagnosis and Treatment of Cancer12 Aug 2021US 2021/0246191 A1
- Substituted imidazoquinolines8 Oct 2020US 2020/0317663 A1
- Recombinant Vaccines and Use Thereof10 Jan 2013US 2013/0011426 A1
Most cited
By later US patents